Introduction
Human CD83 is a 45 kDa glycoprotein which belongs to the by ligands expressed on the cell surface of professional antigen-presenting cells including DC and B cells. Due to its Ig superfamily (1, 2) . Recently the murine cDNA of CD83 has also been cloned, displaying a high degree of conserved expression pattern on antigen-presenting cells in T cell-rich areas, hCD83 and its potential ligand might also directly amino acids between mouse and man at the level of the expressed protein (3) . Human CD83 consists of a single contribute to the activation of T cells. Presently, no data are available, however, that address whether CD83 has a extracellular Ig-like domain, a transmembrane region and a cytoplasmic tail, 39 amino acids long, which lacks any known specific ligand on hematopoetic cells and how CD83 or its ligand may influence immune responses. Here we used consensus signaling motifs. In man, CD83 is mainly expressed on the surface of CD1 ϩ , interdigitating reticulum cells present purified CD83-Ig fusion proteins and an antiserum specific for mCD83 to analyze the expression pattern and kinetics as in the T cells zones of lymphoid organs and on cells of the dendritic lineage (1) . Recent data attribute to dendritic cells well as a possible immunological function of CD83 and its putative ligand in cultures containing spleen cells from (DC) a central role in the activation of naive T lymphocytes and in the generation of primary T cell responses (4,5). Recent DO11.10 TCR transgenic mice. experiments revealed that CD83 on human immature DC is mainly expressed intracellularly and upon maturation of the Methods DC can also be detected on the cell surface (6). CD83, thus, represents a typical surface maturation marker on human Cell lines and reagents DC (7).
To achieve complete activation (8), T cells require a All cell lines were maintained in RPMI medium (Gibco/BRL, Eggenstein, Germany) supplemented with gentamicin, glutasecond co-stimulatory signal (9), which can be provided mine and 10% FCS. A20/7 is a H-2 d B-cell line and J774 is a monocytic cell line. CD83-expressing transfectants were generated by electroporation of 20 µg pFM91-CD83 vector, containing the complete mCD83 cDNA, into 1ϫ10 7 TCR -58α -β -T cells (10), as described earlier (11). Neomycin-resistant clones were expanded and analyzed by flow cytometry using a FACScan (Becton Dickinson, Heidelberg, Germany).
For proliferation assays, spleen cells (2ϫ10 5 /well) from 6-to 8-week-old, homozygous DO11.10tg [specific for chicken ovalbumin (OVA)323-339 peptide in the context of H2-A d ] mice were cultured in 96-well microtiter plates with the indicated, titrated amounts of synthetic, HPLC-purified, chicken OVA323-339 peptide in the presence or the absence of mCD83-Ig fusion proteins, hCD83-Ig, human B7-Ig fusion proteins or purified human Ig at a final concentration of 40 µg/ml. On day 4 of culture 100 µl of each well was removed for IL-2 quantification and the remaining 100 µl was pulsed with [ 3 H]thymidine (0.5 µCi/ml). IL-2 content in the cultures was assessed by [ 3 H]thymidine uptake of the IL-2-dependent cell line CTLL-2 (5ϫ10 3 /well) (12) or by performing an IL-2-specific ELISA. To generate mCD83-Ig fusion proteins, mRNA from in vitro cultured (10 ng/ml IL-4 and 10 ng/ml granulocyte macrophage colony stimulating factor) bone marrow-derived dendritic cells (day 6 of culture) was reverse transcribed using an oligo(dT) primer. The extracellular part of CD83 was amplified with the CD83-specific primer (GATCGATCAAGCTTTCCGCCATGTCGCAAGGCCT-CCAGCTCCT, containing a HindIII site, and GATCGA-TCGGATCCGCCCTGTACTTCCTGAAAGTTGACTC, containing a BamHI site). The resulting CD83 cDNA fragment was cloned into the HindIII-BamHI digested plasmid pcDNA1.1/ ponding to amino acid sequence 17-31 of mCD83.
Staining procedures
Results and discussion For FACS staining, Fc receptors of 3ϫ10 5 of the indicated So far nothing is known about the function and cellular cells were blocked with 10 µg of purified hIg and subsequently distribution of mCD83. Therefore we analyzed the expression incubated (15 min, 4°C) with 1:25 to 1:50 dilution of the antipattern of CD83 ϩ cells by using a CD83 peptide-specific mCD83-specific antiserum or 1:25 to 1:50 dilution preimmune antiserum, since no mAb are available. To demonstrate the serum from the same animal. After washing, Cyt2-labeled specificity of the CD83 antiserum we used CD83 cDNA donkey anti-rabbit Ig (0.5 µg/sample; Dianova, Hamburg, transfected cell lines which clearly stain with the immune but Germany) was added for 10 min at 4°C. Following washing, not with the preimmune serum from CD83 peptide-immunized samples were subsequently stained with phycoerythrin (PE)-rabbits (Fig. 1A) . Moreover, the CD83-specific antiserum conjugated anti-CD4-specific mAb (Caltag, San Francisco, binds to mCD83-Ig in Western blotting but not to hCD83-Ig CA) or PE-conjugated anti-B220-specific mAb (Caltag) for 10 or hCTLA-4 fusion proteins (Fig. 1B) . Flow cytometry analysis min at 4°C. Cells were fixed and subsequently analyzed in a further revealed the expression of CD83 on the surface of the monocytic cell line J774 as well as on bone marrow-derived FACScan (Becton Dickinson). fusion molecules to cultures containing freshly isolated spleen cells from DO11.10 TCR transgenic mice. mCD83-Ig inhibited proliferation (Fig. 3A) as well as IL-2 production (Table 1) . Especially at lower OVA323-339 peptide concentrations there is a significant reduction of IL-2 secretion in mCD83-Igtreated cultures. Although mCD83-Ig fusion proteins are not able to completely reduce the proliferation or IL-2 secretion, we take our results as a first hint that CD83 and its ligand may be involved in the process to fully activate T cells. Purified hIg (not shown) as well as hB7-Ig fusion protein used as controls did not inhibit the antigen-specific proliferation and IL-2 secretion. To rule out that misfolding of hB7-Ig or hCTLA-4-Ig fusion proteins is responsible for the observed lack of inhibition in T cell proliferation assays, we tested the individual Ig fusion proteins on control cell lines. As shown in Fig. 3(B) , hB7-Ig binds specifically to Jurkat T cells, whereas hCTLA-4-Ig fusion proteins specifically stain the B cell line A20. Taken together, these data argue for a correct folding of the employed hB7-Ig and hCTLA-4-Ig fusion proteins.
Since the inhibition of T cell activation indicates binding to a specific ligand for mCD83, which is not present on long- Ig molecules. In contrast, spleen cells from µMT (B cell) knockout mice, which are completely deficient for peripheral B cells, were negative for mCD83-Ig and hCTLA-4-Ig fusion protein binding cells. Thus, the specific ligand for the mCD83 molecule is expressed predominantly on a subpopulation of DC. Cell surface expressed CD83 in the human system was described as a marker for mature dendritic cells (7). Under splenic B cells which do not belong to the class of B1 B cells. In this study we analyzed a possible immunological function our culture conditions used to generate bone marrow-derived DC, we could also observe a variable induction of mCD83 of CD83 as well as of a so far putative CD83 ligand. Using an antiserum specific for the mCD83 molecule as well as surface expression following addition of lipopolysaccharide (data not shown), a typical method to induce maturation of employing a panel of Ig fusion proteins we could show for the first time the cellular distribution and regulation of the DC (14).
To analyze the expression kinetics of CD83 on T cells, we mCD83 molecule and the involvement of a CD83 ligand which is dominantly expressed on B220 ϩ B cells. Because of its used spleen cell cultures from TCR-transgenic DO11.10 mice expressing a TCR specific for the OVA323-339 peptide in the expression kinetics and its cellular distribution, CD83 and its ligand apparently play an important role in the antigen-specific context of H2-A d . As shown in Fig. 2 , parallel to the activation with antigenic OVA323-339 peptide or TCR-specific mAb, the activation of T cells. Since B cells seem to represent the major cell pool of CD83 ligand-positive cells, it will be interesting to expression of CD83 on the surface of CD4 ϩ T cells increases, reaching a high CD83 expression when the T cells proliferate learn how these different cell types interact and how CD83-dependent interactions modulate the immune response. Due and start to secrete IL-2 on day 3 of culture. After 7 days of culture, CD83 surface expression decreases, reaching to our in vitro experiments one could speculate that the interaction of CD83 and its putative ligand induces signaling background levels on day 9 again (data not shown). Cultures containing no additional supplements showed no viable cascades as already known T cell-expressed co-receptors like CD2 or CD28. The lack of conventional signaling motifs CD4 ϩ T cells in the preset FSC/SSC region during FACS analysis and could therefore not be analyzed on day 7.
in the cytoplasmic tail of CD83, however, makes it unlikely that CD83 itself is transducing T cell stimulatory signals but To see whether CD83 (and a putative CD83 ligand) is involved in the activation of T cells, we added mCD83-Ig rather that the CD83 ligand is triggered by binding of the The IL-2 content in supernatant containing the indicated Ig fusion proteins at a concentration of 40 µg/ml of two independent experiments was determined in a standard CTLL assay as described in Methods. Numbers indicate the mean c.p.m. value of triplicates. SD Ͻ 15% in all experiments. binding cells in close contact to blood vessels (unpublished 5 Cella, M., Sallusto, F. and Lanzavecchia, A. 1997 
